Development of diabetes in NOD mice is polygenic and dependent on both major histocompatibility complex (MHC)-linked and non-MHC-linked insulin-dependent diabetes (Idd) genes. In (F, x NOD) backcross analyses using the B10.H-2e7 or B6.PL-Thyl ~ strains as the outcross partner, we previously identified several non-MHC Idd loci, including two located on chromosome 3 (Idd3 and IddlO). In the current study, we report that protection from diabetes is observed in NOD congenic strains having B6.PL-Thyl a-or B10-derived alleles at Idd3 or Idd10. It is important to note that only partial protection is provided by two doses of the resistance allele at either Idd3 or IddlO. However, nearly complete protection from diabetes is achieved when resistance alleles are expressed at both loci. Development of these congenic strains has allowed Idd3 to be localized between Ght2 and D3Mit6, close to the 112 locus.
T
he nonobese diabetic (NOD) t mouse develops autoimmune diabetes and is thought to be a relevant model of human insulin-dependent diabetes mellitus (IDDM). Many features of diabetes are shared when comparing human IDDM with the disease developed by NOD mice (1, 2) . In both species, autoantibodies and T ceils specific for the insulinproducing 3 cells in the pancreas are detected (3) (4) (5) (6) (7) (8) (9) . It has been demonstrated that both CD4 + and CD8 + T cells are required for the destruction of 3 cells in the NOD mouse (10) (11) (12) . In humans, T cell infiltrates are found within the islets of Langerhans and are thought to mediate the autoimmune destruction (13) (14) (15) .
Disease development in the NOD mouse is complex and polygenic. A major genetic component of the disease is a gene (or genes) linked to the MHC, termed IddI in the mouse (16) (17) (18) . The primary candidate genes for the MHC-linked diabetogenic loci are those which encode the ot and 3 chains of I-Ag 7 in NOD mice (19) . Evidence for the role of class II molecules comes from the observation that the transgenic introduction of an I-E ot gene into NOD mice, which results in the expression of I-E, can completely protect from diabetes as well as insulitis (20, 21) . Similar protective effects 1 Abbreviations used in thispaper: Idd, a gene controlling insulin-dependent diabetes; NOD, nonobese diabetic.
have been observed with other I-A and I-E molecules introduced by transgenic technology and conventional breeding strategies (21) (22) (23) (24) (25) . One mechanism for disease protection by non-NOD class II molecules may be that presentation of autoantigens by I-Ag 7 is less efficient or nonexistent (26) , or alternatively, a non-I-Ag 7 cell-specific nonpathogenic immune response may actively suppress the I-AgT-restricted response.
Although diabetes is controlled by a number of genes in the NOD mouse, the individual contribution of each Idd locus can be ascertained using a series of congenic NOD mouse strains, each possessing a resistance allele at a single Idd locus. Such Idd congenic mice are produced by introgressing Iddcontaining chromosomal regions from normal nondiabetic mice into the genome of the NOD strain by repetitive backcrossing. We (24, 25, 27) and others (28, 29) , developed MHC (Iddl) congenic NOD mice, such as NOD.H-2 b, NOD.H-2 "bl, and NOD.H-2 is, and found that these mice are completely protected from diabetes and insulitis. By studying the F1 progeny of the Iddl congenic strain and NOD, the inheritance of protection by one dose of an Idd allele can be established. In the case of (NOD.H-2 b x NOD)F1 mice, insulitis is observed in ,,o50% of female mice, whereas diabetes develops in <5% of female mice (24, 27) . Our long-term goal is to define the inheritance and biologic activity of other Idd loci using the same congenic mouse strategy that proved to be informative in the case of Iddl. The chromosomal locations of some of the non-MHC-linked loci influencing the development of diabetes have been detected in humans and in the NOD mouse. In humans, one locus outside of the MHC has been shown to contribute to disease susceptibility, the insulin gene region on chromosome 11p15 (30, 31) . In a backcross analysis of (NON x NOD)Ft mice to the NOD parent, Idd2 on chromosome 9 was the first non-MHC locus identified that influenced the incidence of diabetes (17) . Additional diabetogenic loci, Icld3, 4, 5, 6, 7, 8, 9 , and 10, have been localized to chromosomes 3 (centromeric), 11, l, 6, 7, 14, 4, and 3 (distal), respectively, from a (B10.H2g 7 x NOD)Ft x NOD backcross analysis (32) (33) (34) (35) (36) . It is interesting to note that NOD homozygosity is not always associated with increase risk of diabetes for all of the Idd loci.
In the case ofldd7 and IddS, the B10 alleles are more diabetogenic and homozygosity for the NOD allele at these loci is protective (33, 35) .
To characterize further the non-MHC-linked Icld loci, we describe several new NOD congenic strains which express the B10-or B6.PL-Thyla-derived allele at Idd3 and/or IddlO.
Results from these strains demonstrate that the non-NOD alleles at Idd3 and IddlO individually contribute to disease protection, although protection is only partial. The combination of resistance alleles at both Idd3 and IddlO on the NOD background results in profound disease protection. This study demonstrates the usefulness of NOD congenic strains of mice in the dissection of autoimmune diabetes.
Materials and Methods
Animals. NOD/MrkTacfBR. (NOD) mice were purchased from Taconic Farms Inc. (Germantown, NY) and C57BL/lOSnJ (B10) and B6.PL-ThyI~ (B6.PL-ThyI a) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). The B6.PL-Thyl a congenic strain was derived at The Jackson Laboratory by backcrossing (B6 x PL)F1 mice to the C57BL/6 (B6) strain with selection for the PL Tttyl allele on chromosome 9. All mice were housed under sterile, specific pathogen-free conditions. NOD mice (K d, I-A sT, D b, and no expression of I-E) were outcrossed to B10 or B6.PL-Thyl ~ mice (both strains express K b, I-A b, and D b, and lack I-E expression) and the resulting F~ mice backcrossed to the NOD parental strain as reported earlier. First backcross mice were selected for homozygosity at the NOD MHC by testing for the expression of I-A b and I-Ag 7 on the surface of PBMC as previously described (24) . Further selection criteria based on the development of diabetes and insulitis are described in Results.
At the fifth or sixth backcross generation, DNA was isolated from peripheral blood leukocytes of mice from pedigrees relatively resistant to diabetes and tested for the presence of genetic markers on chromosome 3. Mice expressing B10 or B6.PL-Thyl ~ alleles at various loci on chromosome 3 were selectively bred and used to develop the congenic lines described in this study. All microsatellite markers, with the exception of D3Nds7 and D3Nds28, have been described previously (35) (36) (37) (38) 
Results
Development of NOD Congenic Strains. The B10 and B6 strains of mice have previously been shown to possess four to five diabetes-resistant loci (18, 29) . To begin defining these loci, we developed a series of NOD-related strains bred for diabetes-resistance after outcrosses to both the B10 and B6.PLThyl a strains. We used the B6.PL-Thyl a strain rather than B6 in order to follow segregation of Idd2, which is linked to the ThyI locus (17) . At the first backcross generation, we selected nondiabetic mice that were homozygous for the NOD MHC, these mice were then continually backcrossed to the NOD strain with selection for diabetes resistance. Diabetes resistance was defined as a lack of spontaneous or cyclophosphamide-induced diabetes and little or no insulitis. Female mice at each backcross were assessed for resistance to cyclophosphamide-induced diabetes and insulitis after the production of at least two litters. Subsequently, in a backcross analysis using the NOD and BIO.H-2 "~ strains, we discovered that a region on chromosome 3 was a major determinant of diabetes susceptibility in the NOD mouse (33, 35) . This linkage to diabetes on chromosome 3 was also observed in a backcross analysis performed with the NOD and B6.PLThyl ~ strains (33, 36) . Two diabetes-resistant strains were still segregating a large section of chromosome 3 derived from either B10 (at the sixth backcross generation) or B6.PLThyI ~ (at the fifth backcross generation). These two congenie strains are described in this report as the NOD.Blff 12-rshb and NOD.B6 It2-rshb strains, respectively (Table 1) . Using a battery of microsatellite markers which are polymorphic between NOD and B10 or B6.PL-Thyl ~ (35) , we continued to backcross these two congenic strains and to screen progeny for additional recombination events on chromosome 3. To facilitate the fine-mapping of the diabetes resistance gene on chromosome 3, such recombinant mice were used to initiate new congenic strains in which smaller portions of non-NOD chromosome 3 DNA were introgressed into the NOD gehome (Table 1) . * The recombinant fraction between loci using data obtained from 60-132 animals.
During the selection process, congenic strains were analyzed for the presence of other chromosomal regions known to contribute to diabetes resistance in the NOD mouse, specifically Idd2, 4, 5, 6, 7, 8, and 9 (35) . In addition, a panel of microsatellite markers sampling the entire genome were used to characterize the congenic strains (35) . Regions outside of chromosome 3 that were detected as non-NOD were replaced with the NOD alleles by selective breeding. As detailed later, segregation analysis of the NOD.B6 It2-~hb strain has been performed and results are consistent with the hypothesis that only regions on chromosome 3 are contributing to diabetes resistance. It is also important to note that the statistical probability of achieving homozygosity at loci unlinked to the selected locus increases with the number of backcrosses performed. All of the congenic strains in the current report were studied at the N6, N7, or N10 generations (see Table 1 ) in which there is a 96.9, 98.4, and 99.8% chance of homozygosity for the NOD allele at unlinked loci (40) .
The NODB6 ~2-7"shb Strain Shows Profound Protection from Diabetes. Development of spontaneous diabetes in male and female NOD.B6 n2-~' shb mice was monitored for 7 mo (Fig.  1, A and B, Table 2 ). Almost complete protection from disease was observed in both female (Fig. 1 A) and male ( Fig.  1 B) NOD.B6 ne-rshb mice; only 2 of 159 (1.2%) females and no males (0/145) developed spontaneous diabetes (Table 2) . This near lack of diabetes is in marked contrast to the parental frequency of disease observed in our NOD colony during this time: 78% in females and 38% in males (Fig. 1, Table 2 ).
(NOD.B6 ~12-r' hb x NOD)F1 mice, which possess only one copy of the protective chromosome 3-derived DNA, showed a reduced, but significant, level of protection from diabetes ( Fig. 1, A and B) . Whereas the disease incidence was reduced by half in F1 females as compared with NOD females (41 vs. 78% incidence of diabetes at 7 mo; p <10-4), male (NOD.B6 ~le-T' hb x NOD)F1 mice remained nearly disease free at 7 mo with only 4 of 132 male F1 mice diabetic by this time. It is striking that with (NOD.B6 ~-Tshb x NOD)F1 mice, the usual twofold higher risk of disease development with NOD females compared with NOD males had increased to a 13-fold difference in disease incidence with 41% of females and 3% of males developing diabetes.
The NOD.B6 ~t2 and NOD.B6 rshb Strains Have Higher Frequency of Diabetes than the NOD.B6 It2-rshb Strain. Since the NOD.B6 m and NOD.B6 r'hb congenic strains essentially divide in half the region introgressed in the NOD.B6 xte-r~hb congenic strain (Table 1) , we expected that one or the other of the two strains would resemble the NOD.B61e-rshb strain with respect to diabetes incidence. To our surprise, neither strain showed the same pattern of protection from diabetes seen in NOD.B6 It2-T~hb mice. In the case of the NOD.B6 tt2 congenic strain (Fig. 1, C and D) , male homozygotes were almost completely protected with only 1 of 84 mice developing diabetes. This value was not significantly different than the mice, respectively (Fig. 1, C-F At Least Two Genes Account for the Resistance to Diabetes in NODB6 n2-7"`hb Mice. The patterns of diabetes resistance observed in the NOD.B6112-r'hb, NOD.B6 I12, and NOD.B6 TM strains led us to hypothesize that at least two linked loci on chromosome 3 accounted for the profound diabetes resistance of the NOD.B6 t12-r' hb congenic strain. Resistance alleles from the B6.PL-Thyl a strain at both loci were required for the near-complete resistance to diabetes. The reduced, but significant resistance to disease observed in the NOD.B6 I12 and NOD.B6 TM strains could then be explained by the fact that each of these strains expresses diabetes resistance via only one of the two loci active in the NOD.B6 Ite-T~hb strain. To address this hypothesis, complementation studies were performed to determine if a combined activity of the putative resistance alleles could be observed.
The frequency of diabetes in (NOD.B6 n2 x NOD.B6T'hb)F1 mice was compared with those of (NOD.B6 ae x NOD)F1, (NOD.B6 TM x NOD)F1 and (NOD.B6 ae-Tshb x NOD)F1 mice (Fig. 2 A) . Remarkably, the frequency of diabetes in (NOD.B6 ne-r~hb x NOD)F1 was equivalent to the frequency observed in (NOD.B6 a2 x NOD.B6rs~b)Ft mice; both of these F~ strains were protected significantly more than either the (NOD.B6 a2 x NOD)F~ or (NOD.B6 TM x NOD)F~ strains (p <0.006 for all comparisons). This observation supports the hypothesis outlined above and suggests that (NOD.BC ~-r~h~ x NOD)F~ and (NOD.B6 ~tz x NOD.B6r'~)F~ mice both have one dose of the B6.PL-Thy1~-derived protective allele at each of the two loci (Idd3 for the centromeric locus and IddlO for the distal locus). In (NOD.B6 ne-r'h~ x NOD)F~ mice, the protective alleles are cis whereas in the (NOD.B6 ae x NOD.B6T,~)F1, the protective alleles are trans.
Observations made with additional F~ strains support the two-gene hypothesis for chromosome 3 (Fig. 2 B) . When two doses of the B6.PL-Thyl ~ allele at Idd3 were present, as in the NOD.B6 ~ strain, 23/81 females developed diabetes. However, when one dose of the B6.PL-ThyI ~ allele at IddlO was present in addition to the two doses of the B6.PL-Thyl ~ allele at Idd3, as in the (NOD.B6 a2-T~ x NOD.B6/t2)Fh fewer females developed disease (6/57, p = 0.0116). Similarly, the NOD.B6 TM strain, which has two doses of the protective allele at IddlO, was less protected from diabetes than (NOD.B6 n2-r~ x NOD.B6r~)F~ mice, which have a single dose of the protective allele at Idd3 in addition to two doses of the protective allele at Idd10 (50/152 vs. 9/61, p = 0.007). It is interesting to note that in female (NOD.B6 a2-r'h~ x NOD.B6rs~)F~ mice, a single dose of the diabetes-resistance allele at Idd3 decreased the incidence of diabetes when it was expressed in the context of resistance at IddlO. A protective effect from a single dose of this same Idd3 allele was not observed in the context of the NOD background in females (see [NOD.B6 It2 x NOD]F1 vs. NOD in Fig. 1 C) .
Localization ofldd3 and Idd10. The lack of complete protection in the presence of one or two doses of the protective B6.PL-ThyI a allele at Idd3 or IddlO makes fine-mapping of either locus by backcross analysis impossible. We therefore selected a strategy in which informative recombination events were fixed on the NOD background and a sufficient number of homozygous mice were examined for their incidence of diabetes. In this way, protection from diabetes by Idd3 and IddlO could be localized to smaller regions of chromosome 3. The NOD.B6 ~ strain is an example of such a congenic (Table  1 ). This mouse was derived from the NOD.B6 n2 strain after an outcross to NOD and subsequent hackcrossing to the NOD parent. A recombination event occurred between D3Ndsl and D3Mit6 during a backcross meiosis. The event was fixed by backcrossing the recombinant mouse to the NOD strain once again in order to produce male and female mice possessing the recombination event. Intercrossing such heterozygous mice produced the homozygous founders of the NOD.B6 ~ strain in which B6.PL-Thyl~-derived alleles are present at D3Ndsl, D3Mit22, and D3Mit51.
It is interesting to note that the NOD.B6 D3N~I strain was not protected from diabetes (Table 2 ). This result places Idd3 centromeric of D3Ndsl and IddlO telomeric of D3Mit51. We next took advantage of the results from NOD mice congenic for regions on chromosome 3 derived from the B10 strain to localize further Idd3 and IddlO (Table 1) . It is highly likely that the B10 and B6.PL-Thyl a strains have the same alleles at both Idd3 and IddlO since the B6 and B10 strains diverged only within the past 40 yr. In addition, the two strains have been shown to be identical at 101 of the 102 microsatellite sequences tested (32) . Moreover, the frequency of diabetes is indistinguishable between the NOD.B10 n2-~'hb strain and the NOD.BC t2-:rshb strain (Table 2) . Similarly, the frequency of diabetes in NOD.B10 TM and NOD.B6 TM mice is not significantly different (Table 2) .
Since the NOD.B10 n2-T~hb strain has fixed a recombination event between D3Nds6 and D3Nds12( Resistance to Diabetes in NODB6 n2-Tshb Mice Segregates with Chromosome 3. To ensure that regions outside of chromosome 3 were not contributing to the results reported, we performed a segregation analysis with the NOD.B6 II2-T~hb congenic strain. (NOD.BC t2-r~hb x NOD)Ft mice were backcrossed to NOD mice and the resulting progeny were monitored for diabetes. The incidence of disease was 52% for females (72/139) and 22% for males (32/147) at 6 mo of age, which is only slightly less than the 6 mo incidence of diabetes in our NOD colony, 74% for females and 28% for males (Fig. 1) . Although a control group of 36 backcross mice showed the expected distribution of F1 and NOD genotypes of 112 (17 Ft and 19 NOD types at D3Nds6) and Tshb (15 F1 and 21 NOD types at D3Nds8), the diabetic mice were enriched for NOD homozygosity at 112 and Tshb.
Only slight enrichment of NOD homozygosity was observed among 49 female diabetics genotyped ifll2 and Tshb loci were considered separately; 30 of the diabetics were NOD at Tshb (61%) and 28 were NOD at 112 (57%). However, consistent with the presence of two diabetes resistance genes on chromosome 3, only 13 of the 49 female diabetics typed were (Fig. 3, A and B) . Despite the profound resistance to diabetes, insulitis was observed in the NOD.B61t2-rshb congenic strain. Insulitis was observed in only 1/10 males and 0/10 females examined at 2 mo of age as compared with 7/10 (p = 0.02) and 10/11 (p <10 -4) ageand sex-matched NOD mice. With time, however, more NOD.B6 It2-Tshb mice developed insulitis; at 5 mo of age, 4/16 females and 2/16 males had insulitis (Fig. 3 B) . The insulitis appeared to have/3 cell-specific cytotoxic potential since treatment of NOD.BC tz-rs~b mice at 7 mo of age with cyclophosphamide caused diabetes in 3/35 females and 7/28 males (Fig. 3 C) .
Since the NOD.BC 12 and NOD.B6 TM strains present a higher frequency of diabetes than the NOD.B6 zte-7"shb strain (Fig. 1) , it was not unexpected that more NOD.B6 I12 and NOD.B6 TM mice developed insulitis by 2 and 5 mo than did NOD.B61t2-r~hb mice (Fig. 3) . Consistent with the expression of insulitis, was the observation that the NOD.B6 ne and NOD.B6 TM strains developed cyclophosphamideinduced diabetes (Fig. 3 C) .
The results with the NOD.B6 m and NOD.B6 T~hb strains, expressing resistance alleles at Idd3 and Idd10, respectively, suggest that resistance alleles at each of these two Idd loci reduce the frequency of insulitis. However, when resistance alleles are present at both loci, as they are in the NOD.B6 ne-rshb strain, the reduction of insulitis is even more profound. This suggests that Idd3 and IddlO act early in the disease process, during the development of insulitis. However, since some NOD.B6 m-rshb mice develop insulitis and a small number develop spontaneous diabetes, the initiation of the autoimmune response to the/3 cells can occur in the absence of NOD alleles at both Idd3 and IddlO.
Discussion
Several years ago at the beginning of the present study, we expected to find three or four dominant-acting and fully penetrant protective alleles from the B10 and B6.PL-Thyl a backgrounds. Previous segregation analyses with the B10 (18) and B6 (41) strains had demonstrated potent protective influences from these normal mice, consistent with the existence of what appeared to be fully recessive NOD-derived diabetes susceptibility loci. Our initial strategy to identify protective B10 or B6.PL-Thyl a alleles at non-MHC-linked diabetogenic loci was to backcross (B10 x NOD)Ft or (B6.PL-ThyI" x NOD)F1 mice to the NOD parental strain and select for pedigrees demonstrating a low frequency of diabetes. We hypothesized that each dominant diabetesresistant allele derived from B10 or B6.PL-Thyl ~ would reduce diabetes by 50%. We bred 23 different pedigrees to ensure that each of the proposed dominant protective alleles would be responsible for disease protection in at least one of the lines. However, with this strategy, we were unable to demonstrate the existence of any single dominant allele from the B10 or B6.PL-Thyl a strains that protected against diabetes. Indeed, the eventual development of the congenic lines described in the present study, which were initiated with the above strategy, relied primarily on the fortuitous observation that male mice were protected from diabetes. In retrospect, this protection was dependent on the pedigrees not 1711 Wicker et al.
recombining between the two linked Idd loci on chromosome 3, Idd3 and IddlO. Unfortunately, by the time we realized that many Idd loci were segregating in the (Bt0.H-2g 7 x NOD) x NOD and (B6.PL-Thyl a x NOD) x NOD backcrosses (33), only two pedigrees remained, eventually becoming the NOD.BIO m-rshb and NOD.B6 zt2-Tsht strains, the other pedigrees were discarded because diabetes resistance could not be maintained.
The development ofldd3 and Iddlo congenic strains of mice has provided a number of insights into the contribution of non-MHC-linked genes to autoimmune diabetes in the NOD mouse. The first, and perhaps most striking finding revealed by the congenic strains, was that two independent Idd loci exist on chromosome 3. Our initial mapping studies pointed to a single locus located near D3Ndsl, termed Idd3 (33) . In that study, there was less than a 1 in 1,000 likelihood of finding Idd3 near I12. We now realize that the initial localization of Idd3 to D3Ndsl was caused by the combined effects of two Idd loci, Idd3 and IddlO, flanking D3Ndsl. In fact, a D3Ndsl NOD congenic strain is not protected from diabetes (Table  2) . A second striking finding from the Idd3 and IddlO congenic strains was that one or two doses of either resistant allele only partially protects from diabetes. Thus, at least in the case of Idd3 and IddlO, NOD alleles at these loci contribute to, but are not absolutely required for, disease development. This is in contrast to NOD strains congenic for resistant alleles at Iddl where complete resistance to diabetes occurs with two doses of the resistant MHC allele and virtually complete resistance with one dose (24, 25, 28, 29) .
Our goal of identifying the gene products of Idd3 and IddlO is made more difficult by the observation that the presence of the NOD allele at either locus is not absolutely required for diabetes. Thus, fine-mapping these two Idd loci using conventional segregation analyses is not possible. We have therefore begun to fine-map Idd3 and Idd10 by identifying potentially informative recombination events and developing new Idd3 and IddlO congenic strains with smaller introgressed regions. Such studies are ongoing and the strategy has been successful at defining smaller chromosomal regions that contain Idd3 and Idd10 (our unpublished observations).
There are several candidate genes for Idd3 and IddlO. One candidate gene for Idd3, Ght2, has been ruled out in the current study since a congenic strain expressing the NOD allele at Glut2 is resistant to diabetes (Tables I and 2 ). It is interesting to note that 112, which is polymorphic between NOD and the B10 and B6 strains (35, 42) , remains a candidate gene for Idd3. However, despite this polymorphism in the structural gene, no functional polymorphism of the lymphokine has been detected (42) . Fcgrl, which encodes the high affinity Fc receptor and for which the NOD strain has a rare mutated allele encoding a defective receptor (36) , remains a candidate gene for IddlO. Other noteworthy candidate genes for IddlO are Csfm and Cd53.
We speculate that, for several of the Idd loci that contribute to disease, the diabetes-susceptibility allele will often be found among inbred strains of mice because it alone does not confer disease susceptibility. These diabetogenic allelic variants could alter lymphocyte homing, the physiology of beta cells within the islets, the establishment of peripheral tolerance, Thl/Th2 balance, or other aspects of the autoimmune response. This model predicts that overlapping, but different sets of Idd loci will be found to segregate depending on the strain that is used to outcross with the NOD. Each nondiabetic inbred strain tested would have a different pattern of alleles at the loci that contribute to the development of diabetes. For example, in an (SWR x NOD) x NOD backcross analysis, no linkage of diabetes to chromosome 3 was detected (Leiter, E., personal communication).
Finally, the development ofldd congenic strains allows gene interactions to be identified. For example, we found that the simultaneous presence of Idd3 and IddIO confers more resistance from diabetes and insulitis than would be expected from the protection provided by either locus alone. Thus, protection caused by these two Idd loci appears to be synergistic rather than additive. It is interesting that a statistical evaluation of the contribution of Idd loci to the development of diabetes in the NOD mouse demonstrated that a multiplicatire epistasis model provides the best description of the observed disease frequency (43) . The molecular basis for the interaction between Idd3 and Idd10 must await the identification of these two genes and their biologic function in autoimmunity.
